세계의 신장암 치료제 시장 보고서(2024년)

Kidney cancer drugs are designed to treat kidney cancer through systemic therapy, reaching cancer cells throughout the body. Various medications may be employed, depending on the type of kidney cancer. These drugs work by targeting key proteins, such as tyrosine kinases, crucial for the growth and survival of cancer cells, or by inhibiting angiogenesis, the formation of new blood vessels that nourish tumors.

The main types of kidney cancer include renal cell carcinoma (RCC), urothelial carcinoma, and others (renal sarcoma, renal lymphoma). Renal cell carcinoma is a condition where malignant cells form in the kidney's tubules. Different products involved in treating kidney cancer include Nexavar (sorafenib), Sutent (sunitinib), Afinitor (everolimus), Voting (pazopanib), Avastin (bevacizumab), Inlyta (axitinib), Torisel (temsirolimus), Proleukin (aldesleukin), and others. These drugs are used by hospitals, clinics, research centers, and similar healthcare facilities.

The kidney cancer drugs market research report is one of a series of new reports from The Business Research Company that provides kidney cancer drugs market statistics, including kidney cancer drugs industry global market size, regional shares, competitors with a kidney cancer drugs market share, detailed kidney cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the kidney cancer drugs industry. This kidney cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer drugs market size has grown strongly in recent years. It will grow from $7.81 billion in 2023 to $8.23 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historic period can be attributed to factors such as increased healthcare expenditure, rapid growth in the elderly population, an increase in pharmaceutical research and development (R&D) expenditure, and advances in cancer drug discovery.

The kidney cancer drugs market size is expected to see strong growth in the next few years. It will grow to $10.12 billion in 2028 at a compound annual growth rate (CAGR) of 5.3%. The forecasted growth in the period ahead can be attributed to factors such as the increasing geriatric population, a rise in healthcare expenditure, an increase in acquisitions and partnerships for drug development, and the high potential of emerging economies. Major trends expected in the forecast period include adopting 3D technology in manufacturing drugs and creating models to provide matrix interactions and more personalized treatments, investing in biomarkers to produce more effective drugs in a smaller time frame, launching or adopting new treatment developments to treat patients and give them a longer survival time, improving treatment by offering personalized medicine, investing in AI solutions to save drug development time and accurately diagnose a patient, and collaborating and partnering with other companies or government bodies to accelerate the development of new drugs.

The surge in the incidence of renal cancer stands out as a significant driver of the kidney cancer drugs market. Lifestyle changes, tobacco consumption, and an unhealthy diet contribute to the proliferation of renal cancer cells. For example, the American Cancer Society reported in January 2022 that approximately 79,000 new cases of kidney cancer (50,290 in men and 28,710 in women) are expected to be diagnosed, resulting in 13,920 fatalities (8,960 in men and 4,960 in women). The majority of diagnoses occur between the ages of 65 and 74, with an average age of diagnosis being 64. Kidney cancer is relatively rare in individuals under the age of 45, emphasizing the driving force behind the growth of the kidney cancer drugs market.

Government initiatives and funding addressing kidney disorders are anticipated to propel the kidney cancer drugs market's growth. Government initiatives and funding provide financial support to entities and projects contributing to public services and the economy. These initiatives enhance disease surveillance, raise awareness, and promote research in kidney disorders. For instance, in July 2022, the United States House Committee on Appropriations initiated investment programs to boost kidney health. This includes $8.5 million in funding for the Centers for Disease Control and Prevention's chronic kidney disease program, aimed at promoting awareness, diagnosis, and treatment. Additionally, a living donation investment of $1 million was allocated to the national living donor assistance center, bringing the total to $8 million for innovation and research. Consequently, government initiatives and funding for kidney disorders play a pivotal role in driving the kidney cancer drugs market's growth.

The kidney (renal) cancer drug market is witnessing a trend toward combination therapy, where the effects of various drugs are combined to reduce the likelihood of cancer-resistant cells developing. The improved understanding of renal cancer causes has led to the development of combination therapy, often combining vascular endothelial growth factor (VEGF) drugs with inhibitors of the mammalian target of rapamycin (mTOR). For instance, in November 2021, Merck & Co., Inc. announced FDA approval for the anti-PD-1 drug KEYTRUDA as adjuvant treatment for renal cell carcinoma (RCC) patients at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy with resection of metastatic lesions.

Major companies in the kidney cancer drugs sector are strategically developing innovative drugs and focusing on obtaining increased approvals to drive market revenues. Drug approvals involve a thorough evaluation by regulatory authorities to ensure safety, efficacy, and quality. In March 2021, AVEO Pharmaceuticals, Inc. launched tivozanib (Fotivda), a kinase inhibitor, approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

In October 2022, LG Chem, Ltd. acquired AVEO Oncology for $566 million. This acquisition positions LG Chem's Life Sciences Division in the U.S., diversifies its pipeline with various oncology treatments, and accelerates LG Chem's growth efforts in the oncology sector. The collaboration aims to establish a global oncology organization with a robust portfolio, spanning from discovery to clinical development, biologics manufacturing, and U.S. commercialization, ultimately broadening access to treatment options. AVEO Oncology is a U.S.-based biopharmaceutical company committed to delivering cancer patients drugs that enhance their quality of life.

Major companies operating in the kidney cancer drugs market report are Pfizer Inc., Novartis AG, Exelixis, Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Bayer AG, Merck & Co., Inc., EUSA Pharma Inc., UroGen Pharma Ltd., Natco Pharma, Arlak Biotech, Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Veropharm, Biocad, Celon Pharma, Amgen Inc ., Biocon Ltd., Rani Therapeutics, Eli Lilly and Company, Abbott Laboratories, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Sanofi, Biogen Inc., AVEO Oncology, Eurofarma Laboratorios S.A., TUTEUR Argentina, Pierre Fabre Group, Celnova Pharma, Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Novo Nordisk A/S, Kitov Pharma Limited, CureTech Ltd., Neopharma

North America was the largest region in the kidney cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global kidney cancer drugs market share during the forecast period. The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the kidney cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The kidney cancer drugs market consists of sales of axitinib (Inlyta), cabozantinib (cabometyx), and pazopanib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Renal Cell Carcinoma (RCC); Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
• 2) By Product: Nexavar (Sorafenib); Sutent (Sunitinib); Afinitor (Everolimus); Votrient (Pazopanib); Avastin (Bevacizumab); Inlyta (Axitinib); Other Products
• 3) By End Users: Hospitals; Clinics; Research Center; Other End-Users
• Companies Mentioned: Pfizer Inc.; Novartis AG; ExelixisInc.; F. Hoffmann-La Roche AG; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kidney Cancer Drugs Market Characteristics

3. Kidney Cancer Drugs Market Trends And Strategies

4. Kidney Cancer Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Kidney Cancer Drugs Market Size and Growth

• 5.1. Global Kidney Cancer Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Kidney Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Kidney Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Kidney Cancer Drugs Market Segmentation

• 6.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Renal Cell Carcinoma
• Urothelial Carcinoma
• Others (Renal Sarcoma, Renal Lymphoma)
• 6.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Nexavar (Sorafenib)
• Sutent (Sunitinib)
• Afinitor (Everolimus)
• Votrient (Pazopanib)
• Avastin (Bevacizumab)
• Inlyta (Axitinib)
• Torisel (Temsirolimus)
• Proleukin (Aldesleukin)
• Other Products
• 6.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Research Center
• Other End-Users

7. Kidney Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Kidney Cancer Drugs Market

• 8.1. Asia-Pacific Kidney Cancer Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Kidney Cancer Drugs Market

• 9.1. China Kidney Cancer Drugs Market Overview
• 9.2. China Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Kidney Cancer Drugs Market

• 10.1. India Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Kidney Cancer Drugs Market

• 11.1. Japan Kidney Cancer Drugs Market Overview
• 11.2. Japan Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Kidney Cancer Drugs Market

• 12.1. Australia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Kidney Cancer Drugs Market

• 13.1. Indonesia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Kidney Cancer Drugs Market

• 14.1. South Korea Kidney Cancer Drugs Market Overview
• 14.2. South Korea Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Kidney Cancer Drugs Market

• 15.1. Western Europe Kidney Cancer Drugs Market Overview
• 15.2. Western Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Kidney Cancer Drugs Market

• 16.1. UK Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Kidney Cancer Drugs Market

• 17.1. Germany Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Kidney Cancer Drugs Market

• 18.1. France Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Kidney Cancer Drugs Market

• 19.1. Italy Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Kidney Cancer Drugs Market

• 20.1. Spain Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Kidney Cancer Drugs Market

• 21.1. Eastern Europe Kidney Cancer Drugs Market Overview
• 21.2. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Kidney Cancer Drugs Market

• 22.1. Russia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Kidney Cancer Drugs Market

• 23.1. North America Kidney Cancer Drugs Market Overview
• 23.2. North America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Kidney Cancer Drugs Market

• 24.1. USA Kidney Cancer Drugs Market Overview
• 24.2. USA Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Kidney Cancer Drugs Market

• 25.1. Canada Kidney Cancer Drugs Market Overview
• 25.2. Canada Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Kidney Cancer Drugs Market

• 26.1. South America Kidney Cancer Drugs Market Overview
• 26.2. South America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Kidney Cancer Drugs Market

• 27.1. Brazil Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Kidney Cancer Drugs Market

• 28.1. Middle East Kidney Cancer Drugs Market Overview
• 28.2. Middle East Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Kidney Cancer Drugs Market

• 29.1. Africa Kidney Cancer Drugs Market Overview
• 29.2. Africa Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Kidney Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Kidney Cancer Drugs Market Competitive Landscape
• 30.2. Kidney Cancer Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Exelixis
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. F. Hoffmann-La Roche AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bristol Myers Squibb Company
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Kidney Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Merck & Co., Inc.
• 31.3. EUSA Pharma Inc.
• 31.4. UroGen Pharma Ltd.
• 31.5. Natco Pharma
• 31.6. Arlak Biotech
• 31.7. Healthkind labs Pvt. Ltd.
• 31.8. SwisscheM Healthcare Pvt.Ltd
• 31.9. Apikos Pharma
• 31.10. Kolaz biotech
• 31.11. CStone Pharma
• 31.12. CARsgen Therapeutics
• 31.13. JW Therapeutics
• 31.14. BeiGene
• 31.15. Takeda Pharmaceuticals

32. Global Kidney Cancer Drugs Market Competitive Benchmarking

33. Global Kidney Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Kidney Cancer Drugs Market

35. Kidney Cancer Drugs Market Future Outlook and Potential Analysis

• 35.1 Kidney Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Kidney Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Kidney Cancer Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer